NCT02219984 START-Register: Survey on Anticoagulated Patients Register
| NCT ID | NCT02219984 |
| Status | Recruiting |
| Phase | — |
| Sponsor | GUALTIERO PALARETI |
| Condition | Atrial Fibrillation |
| Study Type | OBSERVATIONAL |
| Enrollment | 15,410 participants |
| Start Date | 2011-10 |
| Primary Completion | 2025-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 15,410 participants in total. It began in 2011-10 with a primary completion date of 2025-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a phase 4 cohort prospective, open, national, multicentre study that collects data on history of patients treated chronically with anticoagulant drugs, including the novel direct oral anticoagulants (DOACs). The Registry is designed solely for observational purposes and is not intended to have any influence on the treatment of the single patients included. Patients are included when they start the anticoagulant treatment, whatever the drug used, or when they shift from a vitamin K antagonist (VKA) drug to one of the novel direct oral anticoagulants, provided that the therapy is expected to last at least 3 months. The general aims of the study are to provide a better evaluation of efficacy and safety of different treatment options, and to improve our understanding of the risks/benefits of the various anticoagulant drugs and the different therapy options. The Registry is open to the participation of clinical centres or individual professionals (now called Participants) that are involved with management of anticoagulated patients.
Eligibility Criteria
Inclusion Criteria: * age \>= 18 years Exclusion Criteria: * \< 18 years * not willing to sign informed consent
Contact & Investigator
Frequently Asked Questions
Who can join the NCT02219984 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Atrial Fibrillation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02219984 currently recruiting?
Yes, NCT02219984 is actively recruiting participants. Contact the research team at gualtiero.palareti@unibo.it for enrollment information.
Where is the NCT02219984 trial being conducted?
This trial is being conducted at Bologna, Italy.
Who is sponsoring the NCT02219984 clinical trial?
NCT02219984 is sponsored by GUALTIERO PALARETI. The trial plans to enroll 15,410 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.